Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | LIPE | Q05469 | 1/20 | 0.50 |
| ▸ | PAM | P19021 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68930 | 0.94 | CYP4Z1 (0.57) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL1107146 | 0.94 | CYP4Z1 (0.57) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL10299459 | 0.94 | CYP4Z1 (0.57) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL6057577 | 0.94 | CYP4F2 (0.59) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL5034285 | 0.92 | CYP4Z1 (0.59) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL18932531 | 0.92 | CYP4Z1 (0.55) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL6207253 | 0.92 | CYP4Z1 (0.55) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL1179218 | 0.92 | CYP4Z1 (0.55) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL5545889 | 0.92 | CYP4Z1 (0.55) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL85523 | 0.90 | PPID (0.58) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118007442-B | Unidirectional moisture-conducting fabric and preparation method thereof | 广东云蝶园内衣科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-118007442-A | Unidirectional moisture-conducting fabric and preparation method thereof | 广东云蝶园内衣科技有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-118007442-B | Unidirectional moisture-conducting fabric and preparation method thereof | 广东云蝶园内衣科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118007442-A | Unidirectional moisture-conducting fabric and preparation method thereof | 广东云蝶园内衣科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-115739054-A | Preparation and application of carboxylic acid column [5] arene modified attapulgite | 兰州城市学院 | 2023-03-07 | — | — | CN | disclosed |
| EP-3939974-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3939974-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113549010-A | Preparation and application of compound with AMPK agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2021-10-26 | — | — | CN | disclosed |
| EP-3408268-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3408268-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-04-01 | — | — | US | disclosed |
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. | 2005-08-04 | — | — | US | disclosed |
| US-6573384-B1 | 1,4-substituted cyclic amine compound which is useful as a pharmaceutical, and an intermediate for the process | EISAI CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1179532-A1 | PROCESS FOR THE PRODUCTION OF INDOLE DERIVATIVES AND INTERMEDIATES THEREFOR | Eisai Co., Ltd. (JP) | 2002-02-13 | — | — | EP | disclosed |
| EP-0618899-B1 | AROMATIC ESTERS OF PHENYLENEDIALKANOATES AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE | CORTECH INC (US) | 1996-03-13 | — | — | EP | disclosed |
| EP-0618899-A4 | AROMATIC ESTERS OF PHENYLENEDIALKANOATES AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE. | CORTECH INC (US) | 1994-11-02 | — | — | EP | disclosed |
| EP-0618899-A1 | AROMATIC ESTERS OF PHENYLENEDIALKANOATES AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE. | CORTECH INC (US) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993011760-A1 | AROMATIC ESTERS OF PHENYLENEDIALKANOATES AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE | CORTECH, INC. (US) | 1993-06-24 | — | — | WO | disclosed |
| US-5216022-A | Antiischemic agents | CORTECH, INC. (US) | 1993-06-01 | — | — | US | disclosed |
| US-4016194-A | CATALYTIC CARBONYLATION | TEXACO INC. (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | SULT2A1, STS, SULT1A1 | CYP4Z1 1316/4885MAPT 3819/4885LMNA 2902/4885 |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | CYP4Z1 569/4885MAPT 3475/4885LMNA 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.